Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune (NASDAQ:THAR), a clinical-stage biotechnology company, has appointed Prof. David Jones of Newcastle University to its Scientific Advisory Board (SAB). Prof. Jones, an expert in autoimmune liver disease, leads the UK-PBC research consortium and has contributed to stratified therapy in rare liver disease. He joins a newly formed SAB that includes experts from various prestigious institutions.
The company is advancing its lead drug candidate TH104 for pruritus secondary to primary biliary cholangitis (PBC). Tharimmune recently reported positive Phase 1 results for TH104 and received FDA feedback for its upcoming Phase 2 trial, expected to start in the second half of 2024.
Tharimmune (NASDAQ:THAR), un'azienda biotecnologica in fase clinica, ha nominato Prof. David Jones dell'Università di Newcastle nel suo Comitato Consultivo Scientifico (SAB). Il Prof. Jones, esperto in malattie autoimmuni del fegato, guida il consorzio di ricerca UK-PBC e ha contribuito alla terapia stratificata nelle malattie epatiche rare. Si unisce a un nuovo SAB che comprende esperti di varie istituzioni prestigiose.
L'azienda sta portando avanti il suo principale candidato farmacologico TH104 per il prurito secondario alla colangite biliare primaria (PBC). Tharimmune ha recentemente riportato risultati positivi di Fase 1 per TH104 e ha ricevuto feedback dalla FDA per il suo prossimo trial di Fase 2, previsto per iniziare nella seconda metà del 2024.
Tharimmune (NASDAQ:THAR), una empresa de biotecnología en etapa clínica, ha nombrado al Prof. David Jones de la Universidad de Newcastle en su Junta Asesora Científica (SAB). El Prof. Jones, experto en enfermedades autoinmunes del hígado, lidera el consorcio de investigación UK-PBC y ha contribuido a la terapia estratificada en enfermedades hepáticas raras. Se une a una nueva SAB que incluye expertos de varias instituciones prestigiosas.
La empresa está avanzando con su principal candidato a fármaco TH104 para el prurito secundario a la colangitis biliar primaria (PBC). Tharimmune ha reportado recientemente resultados positivos de Fase 1 para TH104 y recibió comentarios de la FDA para su próximo ensayo de Fase 2, que se espera comience en la segunda mitad de 2024.
Tharimmune (NASDAQ:THAR), 임상 단계의 생명공학 회사,는 데이비드 존스 교수를 뉴캐슬 대학교에서 과학 자문위원회(SAB)로 임명했습니다. 존스 교수는 자가면역 간 질환의 전문가로, 영국-PBC 연구 컨소시엄을 이끌고 있으며, 희귀 간 질환의 계층화된 치료에 기여해왔습니다. 그는 다양한 명문 기관의 전문가들로 구성된 새롭게 형성된 SAB에 합류합니다.
회사는 주도 약물 후보인 TH104를 원발성 담즙성 담관염(PBC)으로 인한 가려움증 치료에 진전을 보이고 있습니다. Tharimmune은 최근 1상 긍정적인 결과를 발표했으며, 다가오는 2상 시험에 대한 FDA의 피드백을 받았습니다. 이 시험은 2024년 하반기에 시작될 예정입니다.
Tharimmune (NASDAQ:THAR), une entreprise de biotechnologie en phase clinique, a nommé Prof. David Jones de l'Université de Newcastle dans son Comité Consultatif Scientifique (SAB). Le Prof. Jones, expert en maladies auto-immunes du foie, dirige le consortium de recherche UK-PBC et a contribué à la thérapie stratifiée dans les maladies hépatiques rares. Il rejoint un nouveau SAB qui comprend des experts de diverses institutions prestigieuses.
L'entreprise fait progresser son principal candidat médicament TH104 pour le prurit secondaire à la cholangite biliaire primitive (PBC). Tharimmune a récemment rapporté des résultats positifs de Phase 1 pour TH104 et a reçu des retours de la FDA pour son prochain essai de Phase 2, qui devrait débuter dans la seconde moitié de 2024.
Tharimmune (NASDAQ:THAR), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat Prof. David Jones von der Universität Newcastle in sein Wissenschaftliches Beratungsgremium (SAB) berufen. Prof. Jones, ein Experte für autoimmune Lebererkrankungen, leitet das UK-PBC Forschungskonsortium und hat zur stratifizierten Therapie seltener Lebererkrankungen beigetragen. Er tritt einem neu gebildeten SAB bei, das Experten von verschiedenen angesehenen Institutionen umfasst.
Das Unternehmen entwickelt seinen Hauptkandidaten TH104 zur Behandlung von Juckreiz, der durch primäre biliäre Cholangitis (PBC) verursacht wird. Tharimmune hat kürzlich positive Ergebnisse der Phase 1 für TH104 gemeldet und Feedback von der FDA für seine bevorstehende Phase 2-Studie erhalten, die voraussichtlich in der zweiten Hälfte des Jahres 2024 beginnt.
- Appointment of Prof. David Jones, an international expert in autoimmune liver disease, to the Scientific Advisory Board
- Positive Phase 1 results reported for lead drug candidate TH104
- FDA feedback received for the design of upcoming Phase 2 trial
- Phase 2 trial for TH104 anticipated to start in H2 2024
- None.
BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).
Prof. Jones has earned an international reputation for his work in autoimmune liver disease. He leads the UK-PBC research consortium (MRC Stratified Medicine), which has the world's largest cohort of fully phenotyped primary biliary cholangitis/cirrhosis (PBC) patients. His areas of expertise include stratified therapeutics and symptom management, and his work contributed to the first stratified therapy to reach practice in rare liver disease. He also has an interest in the quality of life of patients with autoimmune liver disease and the mechanisms underpinning key symptoms, which has led to the development of several novel therapies.
Additionally, he is Honorary Consultant Hepatologist with the Newcastle upon Tyne Hospitals NHS Foundation Trust. Prof. Jones holds the position of National Institute for Health and Care Research (NIHR) Dean for Faculty Trainees and is an NIHR Senior Investigator.
"We are honored to welcome Prof. Jones - a renowned scientist with extensive expertise in hepatic pathologies and PBC - to the Tharimmune SAB," said Randy Milby, CEO of Tharimmune. "As we advance our lead drug candidate TH104 for the potential benefit of thousands of patients suffering from pruritus secondary to PBC who lack effective treatment options, we look forward to engaging with Prof. Jones and our entire SAB for valuable real-world and clinical insights."
Prof. Jones joins the newly formed Tharimmune SAB, which is comprised of Andreas Kremer, MD, PhD, Clinician Scientist and Head of Hepatology at University Hospital Zurich; Alan Bonder, MD, AGAF, Associate Professor of Medicine at Harvard University Medical School and Medical Director of Liver Transplant at Beth Israel Deaconess Medical Center; John Lambert, PhD, a leading expert in the field of antibody drug conjugate discovery and development; and Vaughn Smider, MD, PhD, founder and President of the Applied Biomedical Science Institute and adjunct Professor at the Scripps Research Institute.
Earlier this year Tharimmune announced positive Phase 1 results with TH104 and received Type C meeting feedback from the U.S. Food and Drug Administration for the design of the upcoming Phase 2 trial, which it anticipates initiating in the second half of 2024.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104, is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against these and other specified targets. For more information please visit: www.tharimmune.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release.
Contacts:
Tharimmune, Inc.
ir@tharimmune.com
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
SOURCE: Tharimmune, Inc.
View the original press release on accesswire.com
FAQ
Who is the latest addition to Tharimmune's Scientific Advisory Board?
What is Tharimmune's lead drug candidate and its target condition?
When does Tharimmune (THAR) plan to initiate the Phase 2 trial for TH104?
What recent milestones has Tharimmune (THAR) achieved with TH104?
